Expert Review of Endocrinology & Metabolism最新文献_第3页

Long-acting growth hormone in the treatment of children with growth hormone deficiency. 长效生长激素治疗儿童生长激素缺乏症。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/17446651.2025.2486067

Lorenzo Iughetti, Anna Insalaco, Barbara Predieri, Laura Lucaccioni

{"title":"Long-acting growth hormone in the treatment of children with growth hormone deficiency.","authors":"Lorenzo Iughetti, Anna Insalaco, Barbara Predieri, Laura Lucaccioni","doi":"10.1080/17446651.2025.2486067","DOIUrl":"10.1080/17446651.2025.2486067","url":null,"abstract":"Introduction: The introduction of long-acting formulations in recent years is changing the landscape of growth hormone (GH) therapy. Daily recombinant human GH (rhGH) has been the treatment of choice for children and adults with GH deficiency (GHD), since its approval in 1985. However, decreasing adherence to treatment over time has been identified as a cause of the decline in rhGH efficacy, leading to significant efforts to develop long-acting rhGH (LAGH) formulations.Areas covered: A comprehensive analysis of the literature was conducted to evaluate their mechanism of action, pharmacokinetics, pharmacodynamics, efficacy, safety profile, and administration route. The review focuses on the LAGH approved from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of pediatric growth hormone deficiency (PGHD): Lonapegsomatropin, Somatrogon and Somapacitan. We aim to facilitate evidence-based clinical decisions by analyzing the available data on the three LAGH formulations.Expert opinion: Even if current evidence suggests a non-inferiority of all the three LAGH formulations when compared to daily rhGH, long-term concerns persist regarding the non-physiological GH profile associated with LAGH, characterized by weekly instead of daily peaks. Further research and real-life studies are required to better define the long-term efficacy of these formulations.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"169-186"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case-control study on SH2B1 gene variants in obesity and obstructive sleep apnea severity: genetic risk factors in the leptin signaling pathway. 肥胖和阻塞性睡眠呼吸暂停严重程度中 SH2B1 基因变异的病例对照研究：瘦素信号通路中的遗传风险因素。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-03-19 DOI: 10.1080/17446651.2025.2478068

Serkan Kuccukturk, Sebnem Yosunkaya, Mehmet Ali Karaselek, Sennur Demirel, Hasibe Vural

{"title":"A case-control study on SH2B1 gene variants in obesity and obstructive sleep apnea severity: genetic risk factors in the leptin signaling pathway.","authors":"Serkan Kuccukturk, Sebnem Yosunkaya, Mehmet Ali Karaselek, Sennur Demirel, Hasibe Vural","doi":"10.1080/17446651.2025.2478068","DOIUrl":"10.1080/17446651.2025.2478068","url":null,"abstract":"Background: Obstructive sleep apnea (OSA) is a common sleep disorder, frequently observed in obese individuals, with shared mechanisms involving leptin and its receptor, which regulate appetite and energy expenditure. SH2B1 is a key enhancer of signaling in the leptin receptor pathway. This study aimed to investigate the association between SH2B1 variants and OSA.Research design and methods: This case-control study included 160 male patients with OSA and 76 healthy controls, stratified into subgroups based on BMI (≤25 kg/m2 and ≥ 30 kg/m2). Polysomnography and anthropometric measurements were performed, and genotyping of three SH2B1 variants (rs7498665, rs4788102, and rs7359397) was conducted.Results: Mutant genotypes of all three SH2B1 variants were significantly associated with higher BMI. Additionally, normal genotypes of rs4788102 and rs7359397 were associated with higher apnea-hypopnea index (AHI) values, indicating a potential risk for OSA.Conclusion: The findings suggest that while SH2B1 variants are strongly associated with BMI, specific normal genotypes may independently contribute to OSA risk by increasing AHI values.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"241-248"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma vitamin D status and its association with biochemical, clinical and humanistic outcomes in diabetic foot infection patients: a prospective observational study in a tertiary healthcare facility. 血浆维生素D水平及其与糖尿病足感染患者生化、临床和人文预后的关系：一项三级医疗机构的前瞻性观察研究

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-04-09 DOI: 10.1080/17446651.2025.2480374

Shilia Jacob Kurian, Ruby Benson, Murali Munisamy, Kavitha Saravu, Gabriel Sunil Rodrigues, Sunil Krishna M, Vijayanarayana Kunhikatta, Sonal Sekhar Miraj

{"title":"Plasma vitamin D status and its association with biochemical, clinical and humanistic outcomes in diabetic foot infection patients: a prospective observational study in a tertiary healthcare facility.","authors":"Shilia Jacob Kurian, Ruby Benson, Murali Munisamy, Kavitha Saravu, Gabriel Sunil Rodrigues, Sunil Krishna M, Vijayanarayana Kunhikatta, Sonal Sekhar Miraj","doi":"10.1080/17446651.2025.2480374","DOIUrl":"10.1080/17446651.2025.2480374","url":null,"abstract":"Background: The study aimed to determine the association of vitamin D3 status with biochemical, clinical, and quality of life (QoL) in diabetic foot infection (DFI) patients.Research design and methods: A longitudinal study was conducted in a tertiary care hospital. Baseline biochemical (glycemic, renal, plasma vitamin D3), clinical, and QoL data of the DFI patients were collected. Patients were followed up with over the telephone for four months to assess clinical outcomes (healed/not healed). A subgroup analysis was performed to investigate the effect of vitamin D3 supplementation.Results: Eighty-nine DFI patients were enrolled, with a median age of 55 years and a male predominance (89.9%). A significant association between vitamin D3 levels and clinical outcome was not observed (p = 0.66). A moderate correlation was observed with the neutrophil-lymphocyte ratio (r = 0.24, p = 0.02). Regarding QoL, emotions (domain) were significantly associated with vitamin D3 levels (p < 0.01). The subgroup analysis showed that vitamin D3 supplements did not affect the clinical outcome.Conclusion: The plasma vitamin D3 levels and vitamin D3 supplements do not significantly affect the biochemical, clinical, and humanistic outcomes, indicating vitamin D3 did not have a positive effect on DFI patients.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"233-239"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics. SGLT-2抑制剂可能降低噻嗪类药物和利尿剂患者痛风风险。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-03-15 DOI: 10.1080/17446651.2025.2480695

Kannan Sridharan

引用次数: 0

The application of 3D printing technology in the treatment of diabetic foot ulcers: an integrated strategy for glycemic control and wound care. 3D打印技术在糖尿病足溃疡治疗中的应用：血糖控制和伤口护理的综合策略。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-03-13 DOI: 10.1080/17446651.2025.2467658

Ying-Ju Liao, Chao-Yi Chen, Hsien-Te Lin, Dee Pei, Yao-Jen Liang

{"title":"The application of 3D printing technology in the treatment of diabetic foot ulcers: an integrated strategy for glycemic control and wound care.","authors":"Ying-Ju Liao, Chao-Yi Chen, Hsien-Te Lin, Dee Pei, Yao-Jen Liang","doi":"10.1080/17446651.2025.2467658","DOIUrl":"10.1080/17446651.2025.2467658","url":null,"abstract":"Introduction: Diabetic foot ulcers (DFUs) are a severe complication of diabetes, often leading to amputation. Hyperglycemia induced nerve and vascular damage significantly increases DFU risk. The advent of 3D printing technology presents a revolutionary concurrently address glycemic control and wound management, potentially improving patient adherence and offering a more holistic treatment strategy.Methods: This article reviews current oral antidiabetic medications and explores the potential of innovative 3D printing technology to develop extended release tablets in two distinct release profiles. Additionally, it investigates the application of this technology in creating novel wound dressing solutions aimed at facilitating DFU healing. .Results: The integration of 3D printing technology enables the production of customized, extended-release oral medications that optimize glycemic control while minimizing fluctuations in blood sugar levels. Furthermore, 3D-printed wound dressings demonstrate promising potentialfor enhancing wound healing by providing personalized structural support and controlled drug delivery.Conclusion: A multidisciplinary approach that integrates advanced wound care and diabetes management is crucial to address the escalating challenges posed by DFUs. Leveraging3D printing technology to develop sustained-release medications and innovative wound dressingsmay significantly improve DFU outcomes and improve the quality of life for individuals with diabetes.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"201-209"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the controversies of adult growth hormone deficiency diagnosis. 成人生长激素缺乏症诊断争议综述。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/17446651.2025.2480699

Daniela Cuboni, Luigi Simone Aversa, Silvia Grottoli, Ezio Ghigo, Valentina Gasco

{"title":"An overview of the controversies of adult growth hormone deficiency diagnosis.","authors":"Daniela Cuboni, Luigi Simone Aversa, Silvia Grottoli, Ezio Ghigo, Valentina Gasco","doi":"10.1080/17446651.2025.2480699","DOIUrl":"10.1080/17446651.2025.2480699","url":null,"abstract":"Introduction: Growth hormone (GH) not only drives growth but also has significant metabolic, structural, and quality-of-life impacts. While GH deficiency (GHD) in childhood impairs growth, in adulthood, it leads to metabolic syndrome and multisystem functional abnormalities, collectively termed adult GHD syndrome. Despite being recognized for decades, adult GHD syndrome continues to pose diagnostic and therapeutic challenge.Areas covered: The aim of this review is to analyze the main controversies that persist in diagnosing adult GHD more than 30 years after the initial studies demonstrating the existence of GHD syndrome in adulthood.Expert opinion: The only reliable method for diagnosing adult GHD is demonstrating the failure of GH levels to rise above a specific threshold following pharmacological stimulation tests. Various tests are available, and the choice of the most appropriate one depends on the clinical context, the presence of potential contraindications, and the availability of specific pharmacological agents. It is also important to note that the reproducibility of some stimulation tests for diagnosing adult GHD has been questioned. The GH cutoff values considered diagnostic for GHD differ depending on the test used, are significantly influenced by the individual's body composition and age as well as by assay method employed.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"187-200"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetes mellitus and HbA1c as predictors of mortality in hospitalized COVID-19 patients. 糖尿病和HbA1c作为COVID-19住院患者死亡率的预测因子

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1080/17446651.2025.2469627

Praveen Gupta, Sandeep Bansal, Ira Balakrishnan, Anunay Gupta

{"title":"Diabetes mellitus and HbA1c as predictors of mortality in hospitalized COVID-19 patients.","authors":"Praveen Gupta, Sandeep Bansal, Ira Balakrishnan, Anunay Gupta","doi":"10.1080/17446651.2025.2469627","DOIUrl":"10.1080/17446651.2025.2469627","url":null,"abstract":"Background: The role of diabetes mellitus (DM) in hospitalized COVID-19 patients and of HbA1c in hospitalized COVID-19 patients with DM were not studied adequately in the past.Research design and methods: It was a retrospective cohort study. In this study, data from 305 hospitalized COVID-19 patients was analyzed. The study objective was to determine the association of DM with in-hospital mortality in COVID-19 patients. Another study objective was to determine the association of HbA1c with mortality in COVID-19 patients with DM.Results: In this retrospective study, DM was present in 41.3% (126/305) of the study population. The multivariate Cox regression analysis showed a significant association between DM and mortality (adjusted hazard ratio (aHR): 2.116, 95% CI: 1.088-4.116, p = 0.027). The median HbA1c in diabetic patients was 8.9% (7.5-11.0). HbA1c was found to be associated with mortality in diabetic patients in the multivariate cox-regression analysis (aHR:1.272, 95% CI: 1.028-1.574, p = 0.027). The multivariate Cox regression analysis also showed the association of HbA1c (10.5%≤HbA1c > 10.5%) as a dichotomous variable with in-hospital mortality (aHR: 2.53, 95% CI: 2.606-194.81, p = 0.005) in diabetic patients.Conclusions: DM was independently associated with mortality in hospitalized COVID-19 patients in the multivariate analysis. In COVID-19 patients with DM, HbA1c was associated with mortality as a continuous and dichotomous variable in the multivariate analysis.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"221-232"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A research-based, current approach to diabetes-related acute foot infections and chronic osteomyelitis. 以研究为基础的糖尿病相关急性足部感染和慢性骨髓炎的当前方法。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-03-04 DOI: 10.1080/17446651.2025.2474110

Javier Aragón-Sánchez, Gerardo Víquez-Molina, Ilker Uçkay, José María Rojas-Bonilla, Benjamin A Lipsky

{"title":"A research-based, current approach to diabetes-related acute foot infections and chronic osteomyelitis.","authors":"Javier Aragón-Sánchez, Gerardo Víquez-Molina, Ilker Uçkay, José María Rojas-Bonilla, Benjamin A Lipsky","doi":"10.1080/17446651.2025.2474110","DOIUrl":"https://doi.org/10.1080/17446651.2025.2474110","url":null,"abstract":"Introduction: Diabetic foot infections (DFIs) and diabetic foot osteomyelitis (DFO) are common and serious complications in patients with diabetes, often leading to severe morbidity (including amputation) and even mortality. Professional footcare, prompt diagnosis and appropriate treatment are crucial to preventing limb loss and improving outcomes in infections.Areas covered: This narrative review addresses the management of all DFIs, including the approach to clinical evaluation, appropriate diagnostic methods, and optimal therapeutic strategies. We specifically address key areas in antibiotic therapy, and surgical interventions and techniques. Based on our literature review and extensive, multidisciplinary experience, we developed a novel treatment flowchart specifically for the management of DFO.Expert opinion: Managing DFIs, including DFO, requires a multidisciplinary approach tailored to each patient's clinical presentation. While antibiotics, surgery, and wound care each play a crucial role, the decision-making process should always consider the infection's severity and chronicity. Our proposed flowchart for DFO management emphasizes the importance of logically-sequenced, easy to apply and tailored interventions to prevent unnecessary amputations and improve outcomes. Further research is needed to further refine this flowchart in clinical practice and demonstrate its effectiveness.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations between dose-response of serum creatinine and type 2 diabetes mellitus risk: consistent and robust evidence from a systematic review and meta-analysis. 血清肌酐的剂量反应与2型糖尿病风险之间的关系：来自系统评价和荟萃分析的一致和强有力的证据

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-03-01 Epub Date: 2024-12-18 DOI: 10.1080/17446651.2024.2436890

Vu Thi Minh Phuong, Vu Thi Quynh Chi, Nguyen Di Khanh, Tran Quang Duc, Ngo Huy Hoang

{"title":"Associations between dose-response of serum creatinine and type 2 diabetes mellitus risk: consistent and robust evidence from a systematic review and meta-analysis.","authors":"Vu Thi Minh Phuong, Vu Thi Quynh Chi, Nguyen Di Khanh, Tran Quang Duc, Ngo Huy Hoang","doi":"10.1080/17446651.2024.2436890","DOIUrl":"10.1080/17446651.2024.2436890","url":null,"abstract":"Background: Skeletal muscle is the key target of insulin action. Therefore, a reduction in skeletal muscle mass may trigger insulin resistance, a mechanism of diabetes. Creatinine is the only metabolite of creatine phosphate in the skeletal muscle. Exploring the association between serum creatinine level and T2DM is helpful for the early identification and prevention of T2DM.Research design and methods: Five electronic databases, PubMed, Scopus, Web of Science, Embase, and Epistemonikos, were searched for relevant articles published up to June 2024. Cohort studies and case-control studies were evaluated using the Joanna Briggs Institute (JBI) checklist. The random-effects model calculated the pooled risk ratio and 95% confidence intervals (CIs) based on a heterogeneity test (I2 statistics). Egger's test was used to evaluate publication bias.Results: The pooled RR of diabetes type 2 for the lowest versus the highest serum creatinine was 1.39 (95% CI: 1.17-1.64); I2 = 90.1%; p = 0.002. We found a non-linear association between low serum creatinine level and T2DM risk (pNonlinearity = 0.02), and a decrease of each 0.1 mg/dL serum creatinine increases 1% risk of T2DM [RR = 1.49 (95% CI: 1.17-2.82), I2 = 0%, p = 0.999].Conclusions: This meta-analysis offers evidence of the negative relationship between serum creatinine levels and the risk of developing T2DM in a linear dose-response pattern.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"153-161"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database. 在一个真实世界的数据库中，2型糖尿病患者口服与皮下塞马鲁肽两年后的体重减轻结果

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.1080/17446651.2025.2462100

Jimmy Kwon, Diana Thiara, Jonathan H Watanabe

{"title":"Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.","authors":"Jimmy Kwon, Diana Thiara, Jonathan H Watanabe","doi":"10.1080/17446651.2025.2462100","DOIUrl":"10.1080/17446651.2025.2462100","url":null,"abstract":"Background: Interest has grown in glucagon-like peptide-1 receptor-agonist (GLP-1 RA) semaglutide long-term outcomes. This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.Research design and methods: Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.Results: Subcutaneous users experienced a mean percentage weight loss of 7.5% (16.7 pounds) with 58.7% and 32.9% achieving ≥5% and ≥10% loss, respectively. Oral users lost 4.4% (8.7 pounds) with 50.9% and 17.5% achieving ≥5% and ≥10% loss, respectively. Significant differences existed between formulations in mean percentage weight change (p-value <0.01) and proportion achieving ≥10% loss (p-value = 0.03), but not in proportion achieving ≥5% loss (p-value = 0.34). Outcomes differed by age within oral semaglutide (p-value = 0.02). Regression analyses adjusted for confounders yielded similar findings.Conclusion: Subcutaneous users achieved superior weight loss compared to oral users. Older oral users experienced better weight loss compared to younger users. However, no differences were observed between subcutaneous users.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"163-168"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0